Tempo Pharmaceuticals Garners $8,000,000 Series B Financing

  • Feed Type
  • Date
    1/3/2008
  • Company Name
    Tempo Pharmaceuticals
  • Mailing Address
    161 First Street Cambridge, MA 02142
  • Company Description
    Tempo Pharmaceuticals is a private biopharmaceutical company focused on the development of novel, nanotechnology-based therapeutics in the areas of oncology, autoimmune and inflammatory diseases. The Company has assembled a world-class management team, board of directors and scientific advisory board that collectively have a significant track record of business building, product development and scientific breakthroughs from companies and institutions such as Millennium Pharmaceuticals, Pfizer, Pharmacia, the Massachusetts Institute of Technology, Harvard Medical School, MD Anderson, Fox Chase Cancer Center and the Arizona Health Center.
  • Website
    http://www.tempopharmaceuticals.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $8,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    Proceeds from the financing will be used to accelerate the development of Tempo’s preclinical pipeline of multi-compartmental, nanoparticle-based drugs that have the potential to substantially improve the efficacy and safety of existing and new therapeutics.
  • M&A Terms
  • Venture Investor
    Polaris Venture Partners
  • Venture Investor
    Venrock
  • Venture Investor
    Bessemer Venture Partners
  • Venture Investor
    Alexandria Real Estate Equities, Inc.

Trending on Xconomy